1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
7Lok AS,Lai CL,Leung N,et al.Long term safety of lamivudine treatment in patients with chronic hepatitis B[J].Gastroenterology,2003,125(6):1714-1722.
8Lok AS.The maze for the treatment of hepatitis B[J].N Engl J Med,2005,352(26):2743-2746.
9Jia-Zhang Xu Zhi-Guo Yang Mei-Zhao Le Mao-Rong Wang Chang-Lun He Yun-Hua Sui Institute of Hepatology,the 81st Hospital of PLA,Nanjing 210002,Jiangsu Province,ChinaDepartment of Pathology,the 81st Hospital of PLA,Nanjing 210002,Jiangsu Province,China.A study on pathogenicity of hepatitis G virus[J].World Journal of Gastroenterology,2001,7(4):547-550. 被引量：8
10Liaw YE,Chien RN,Yeh CT,et al.Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy[J].Hepatology,1999,30(2):567-572.
7Zhang XX, Liu CM, Gong QM, et al. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J Gastroenterolo Hepatolo, 2003, 1353-1357.
8Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut, 2000, 46: 562-568.
9Maria Buti, Rafael Esteban. Entecavir, FTC, L-RMAU, LdT and others. J Hepatol, 2003, 39: S139-S142.
10Kirishima T, Okanoue T, Daimon Y, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol, 2002, 37: 259-265
3Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association.肝衰竭诊疗指南[J].中华肝脏病杂志,2006,14(9):643-646. 被引量：830
5European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B[J]. J Hepatol, 2009, 50(2):227-242.
6Tillmann HL, Hadem J, Leifeld L, et al. Safely and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a muhicenter experience[J]. J Viral Hepat, 2006, 13(4):256-263.
7Tsubota A, Arase Y, Suzuki Y, et al. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B[J]. J Gastroenterol Hepatol, 2005, 20(3):426-432.
8Liaw YF, Leung N, Kao JH, et al Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update[J]. Hepatol Int, 2008, 2(10):263-283.
9Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL)[J]. Hepatol Int, 2009, 3(1): 269-282.
10Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B[J]. Gastroenterology, 2003, 125(6):1714-1722.
